Clinical biomarkers in drug discovery and development (original) (raw)
Roberts, S. A. Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov. Devel.6, 66–80 (2003). CASPubMed Google Scholar
Laska, D. et al. Characterization and application of a vinblastine-selected Caco-2 cell line for evaluation of P-glycoprotein. In Vitro Cell. Devel. Biol. Anim.38, 401–410 (2002). CAS Google Scholar
Yuan, R. P. et al. In vitro metabolic interaction studies: Experience of the Food and Drug Administration. Clin. Pharmacol. Ther.66, 9–15 (1999). CASPubMed Google Scholar
Schadt, E. E., Monks, S. A. & Friend, S. H. A new paradigm for drug discovery: integrating clinical genetic, genomic and molecular phenotype data to identify drug targets. Biochem. Soc. Trans.31, 437–443 (2003). Discussion of the potential value in a drug discovery setting of combining genetic analyses with gene expression studies to discover and validate therapeutic targets for complex phenotypic traits. This approach will also be applicable to the search for biomarkers. CASPubMed Google Scholar
van de Vijver, M. et al. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347, 1999–2009 (2002). Expression patterns of 70 genes revealed 2 signatures correlating clearly with good and poor prognosis independently of axillary lymph node involvement. This study has important lessons for the clinical and investigational use of microarray approaches in oncology today. CASPubMed Google Scholar
Lesko, L. J. & Woodcock, J. Pharmacogenomic-guided drug development: Regulatory perspective. Pharmacogenomics J.2, 20–24 (2002). CASPubMed Google Scholar
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & (CBER). Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (2002).
Rolan, P., Atkinson, A. & Lesko, L. J. Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on optimizing drug development. Clin. Pharm. Ther.73, 284–291 (2003). Google Scholar
De Gruttola, V. G. et al. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop. Control. Clin. Trials22, 485–502 (2001). CASPubMed Google Scholar
De Meyer, G. & Shapiro, F. Biomarker development: The road to clinical utility. Curr. Drug Discov.12, 23–27 (2003). Google Scholar
Atkinson, A. J., Jr. et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69, 89–95 (2001). Google Scholar
Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med.8, 431–440 (1989). CASPubMed Google Scholar
Sormani, M. P., Bruzzi, P., Comi, G. & Filippi, M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology58, 417–421 (2002). PubMed Google Scholar
Lin, D. Y., Fleming, T. R. & De Gruttola, V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat. Med.16, 1515–1527 (1997). The authors measure the extent to which a biological marker is a surrogate endpoint for a clinical event by the proportional reduction in the regression coefficient for the treatment indicator due to the inclusion of the marker in the Cox regression model, then estimate this proportion by applying the partial likelihood function to two Cox models postulated on the same failure time variable. One can construct confidence intervals for the proportion by using the direct normal approximation to the point estimator or by using Fieller's theorem. Extensive simulation studies demonstrate that the proposed methods are appropriate for practical use. The method is applied to HIV/AIDS clinical trials. CASPubMed Google Scholar
Flandre, P. & Saidi, Y. Estimating the proportion of treatment effect explained by a surrogate marker. Stat. Med.16, 1515–1527 (1997). Google Scholar
Cowles, M. K. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker. Stat. Med.21, 811–834 (2002). The 'proportion of treatment effect' (PTE) captured by a surrogate endpoint is a frequentist measure intended to address the question of whether trials based on a surrogate endpoint reach the same conclusions as would have been reached using the true endpoint. The authors developed a Markov chain Monte-Carlo-based method for estimating the Bayesian posterior distribution of PTE. Obtaining the full posterior distribution enables direct statements such as 'the posterior probability that PTE >0. 5 is 0.085'. Furthermore, credible sets do not depend on asymptotic approximations and can be computed using data sets for which the frequentist methods might be inaccurate or even impossible to apply. PubMed Google Scholar
Buyse, M. & Molenberghs, G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics54, 1014–1029 (1998). CASPubMed Google Scholar
Congress, O. h. f. Senate Bill 830 Food and Drug Administration Modernization Act of 1997. 10 (1997).
Temple, R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA.282, 790–795 (1999). CASPubMed Google Scholar
Alonso, A., Geys, H., Molenberghs, G. & Vangeneugden, T. Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology. J. Biopharm. Stat.12, 161–178 (2002). PubMed Google Scholar
Streiner, D. & Norman, G. Health Measurement Scales: A Practical Guide to Their Development and Use (Oxford University Press, Oxford, 1995). Google Scholar
Bossuyt, P. & Reitsma, J. B. The STARD Initiative. Lancet361, 71 (2003). A STARD steering committee did an extensive literature search and extracted a list of 75 potential items which were consolidated to form a 25-item checklist and led to the development of a flow diagram for diagnostic studies to communicate vital information about the design of a study — including method recruitment and the order of test execution — and the flow of participants in a transparent manner. The STARD group assembled the final, single-page checklist that is published online. PubMed Google Scholar
Crum, W. R., Scahill, R. I. & Fox, N. C. Automated hippocampal segmentation by regional fluid registration of serial MRI: Validation and application in Alzheimer's disease. Neuroimage13, 847–855 (2001). CASPubMed Google Scholar
Rolan, P. The contribution of clinical pharmacology surrogates and models to drug development — a critical appraisal. Br. J. Clin. Pharmacol.44, 219–225 (1997). CASPubMedPubMed Central Google Scholar
Wesnes, K., Simpson, P. & Kidd, A. An investigation of the range of cognitive impairments induced by scopolamine 0. 6 mg s. c. Hum. Psychopharmacol.3, 27–41 (1988). Google Scholar
Kitagawa, H. et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology28, 542–551 ((2003)). CASPubMed Google Scholar
Huestis Marilyn, A. et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry58, 322–328 (2001). Google Scholar
Lonn, E. The use of surrogate endpoints in clinical trials: Focus on clinical trials in cardiovascular diseases. Pharmacoepidemiol. Drug Saf.10, 497–508 (2001). This review provides a definition of surrogate endpoints, proposes practical criteria for establishing their validity, outlines some of the advantages, disadvantages and specific statistical considerations associated with their use in clinical trials and attempts to also highlight drug approval issues associated with the use of these endpoints. A number of examples are also provided related to the use of surrogate endpoints in clinical trials with special emphasis on their use in cardiovascular medicine. CASPubMed Google Scholar
Daniels, M. J. & Hughes, M. D. Meta-analysis for the evaluation of potential surrogate markers. Stat. Med.16, 1965–1982 (1997). CASPubMed Google Scholar
Gail, M. H., Pfeiffer, R., van Houwelingen, H. C. & Carroll, R. J. On meta-analytic assessment of surrogate outcomes. Biostat.1, 231–246 (2000). CAS Google Scholar
Becker, N. G. & Marschner, I. C. Advances in medical statistics arising from the AIDS epidemic. Stat. Methods Med. Res.10, 117–140 (2001). CASPubMed Google Scholar
Lesko, L. J. & Atkinson, A. J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Ann. Rev. Pharmacol. Toxicol.41, 347–366 (2001). Biomarkers will play an increasingly important role in all phases of drug development including regulatory review although only a few of these biomarkers will become established well enough to serve in regulatory decision making as surrogate endpoints. Even generally accepted surrogate endpoints are unlikely to capture all the therapeutic benefits and potential adverse effects a drug will have in a diverse patient population. Accordingly, combinations of biomarkers probably will be needed to provide a more complete characterization of the spectrum of pharmacological response. In the future, pharmacogenomic approaches, including those based on differential expression of gene arrays, will provide panels of relevant biomarkers that can be expected to transform the drug development process. CAS Google Scholar
Pearson, T. A. et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice — A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation107, 499–511 (2003). PubMed Google Scholar
Fleming, T. R. & DeMets, D. L. Surrogate end points in clinical trials: are we being misled?[comment]. Ann. Intern. Med.125, 605–613 (1996). CASPubMed Google Scholar
Colburn, W. A. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J. Clin. Pharmacol.40, 1419–1427 (2000). CASPubMed Google Scholar
Morris, J. C. et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol.58, 397–405 (2001). CASPubMed Google Scholar
de Leon, M. J. et al. Prediction of cognitive decline in normal elderly subjects with 2-(18F)fluoro-2-deoxy-D-glucose/ positron-emission tomography (FDG/PET). Proc. Natl Acad. Sci. USA98, 10966–10971 (2001). CASPubMed Google Scholar
Jack, C. R. et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology55, 484–489 (2000). PubMedPubMed Central Google Scholar
Hodis, H. N. et al. Estrogen in the prevention of atherosclerosis — a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.135, 939–953 (2001). CASPubMed Google Scholar
Choudhury, R. P., Fuster, V., Badimon, J. J., Fisher, E. A. & Fayad, Z. A. MRI and characterization of atherosclerotic plaque: Emerging applications and molecular imaging. Arterioscler. Thromb. Vasc. Biol.22, 1065–1074 (2002). Comprehensive review of MRI characterization of composition and microanatomy of plaque. The use of MRI in both human disease and experimental models in animals is discussed CASPubMed Google Scholar
Yuan, C. P. et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation105, 181–185 (2002). PubMed Google Scholar
Corti, R. et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow up by high resolution noninvasive magnetic resonance imaging. Circulation106, 2884–2887 (2002). Groundbreaking study using non-invasive methodology to show vascular remodelling and treatment of vessel wall disease. The technique is of importance to assess new therpaeutic approaches that treat vessel wall lesions without altering biomarkers such as cholesterol. CASPubMed Google Scholar
Stefanadis, C. M. D. et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. Circulation99, 1965–1971 (1999). CASPubMed Google Scholar
Rudd, J. H. F. et al. Imaging atherosclerotic plaque inflammation with [18f]-fluorodeoxyglucose positron emission tomography. Circulation105, 2708–2711 (2002). CASPubMed Google Scholar
De Franco, A. C. & Nissen, S. E. Coronary intravascular ultrasound: implications for understanding the development and potential regression of atherosclerosis. Am. J. Cardiol.88, 7M–20M (2001). CASPubMed Google Scholar
Nissen, S. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am. J. Cardiol.89, 24B–31B (2002). Description of the evolution, and advantages, of the most advanced imaging technique in use today in clinical trials for the study of atherosclerosis progression and regression. PubMed Google Scholar
Nieman, K. et al. Reliable noninvasive coronary angiography with fast submillimeter multislice spiral computed tomography. Circulation106, 2051–2054 (2002). PubMed Google Scholar
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994). Landmark study linking cholesterol lowering to coronary mortality and morbidity endpoints.
Heart Protection study collaborative group (2002) MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet360, 7–22 (2002). One of the largest ever trials of the long-term effects of sustained lowering of low-density lipoprotein cholesterol on vascular and non-vascular mortality and major morbidities. Findings showed expected beneficial effects on heart disease and, surprisingly, that simvastatin reduced the incidence of ischaemic stroke, as this event is not well correlated with high cholesterol levels.
Taubes, G. Cardiovascular disease: Does inflammation cut to the heart of the matter? Science296, 242–245 (2002). CASPubMed Google Scholar
Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342, 836–843 (2000). CASPubMed Google Scholar
van der Wal, A. C. et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart80, 14–18 (1998). CASPubMedPubMed Central Google Scholar
Albert, M. A., Danielson, E., Rifai, N. & Ridker, P. M. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA286, 64–70 (2001). CASPubMed Google Scholar
Szalai, A. J., Cooper, G. S., McCrory, M. A. & Kimberly, R. P. Association between a GT-repeat polymorphism in the intron of the C-reactive protein (CRP) gene and plasma CRP. FASEB J.15, A685 (2001). Google Scholar
Sides, G. D. QT interval prolongation as a biomarker for Torsades de Pointes and sudden death in drug development. Dis. Markers18, 57–62 (2002). CASPubMedPubMed Central Google Scholar
Herman, E. H. et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol.48, 297–304 (2001). CASPubMed Google Scholar
Schaefer, P. W. et al. Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging. Am. J. Neuroradiol.23, 1785–1794 (2002). PubMed Google Scholar
Wintermark, M. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann. Neurol.51, 417–432 (2002). Studies show that perfusion CT is an accurate predictor of final infarct size allowing early decisions on management of acute stroke patints and providing a potentuial endpoint for novel neuroprotective agents. PubMed Google Scholar
Morrish, P., Bailey, D., Sawle, G. & Brooks, D. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry64, 314–319 (1998). CASPubMedPubMed Central Google Scholar
Grundman, M. et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J. Mol. Neurosci.19, 23–27 (2002). CASPubMed Google Scholar
Jacobs, L. D. et al. Intramuscular interferon-β-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med.343, 898–904 (2000). A recent example of the use of MR in multiple sclerosis diagnosis and treatment. The use of MR in drug evaluation and labelling can be seen by reading the PDR for interferon-β1a. CASPubMed Google Scholar
Jack, C. R. et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology60, 253–260 (2003). Demonstrates the consistency of MRI measurements of hippocampus across multiple sites giving confidence that multicenter studies to monitor Alzheimer's disease progression and drug treatment effects using MR as biomarker are technically feasible. PubMedPubMed Central Google Scholar
Fox, N. C., Cousens, S., Scahill, R., Harvey, R. J. & Rossor, M. N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease — power calculations and estimates of sample size to detect treatment effects. Arch. Neurol.57, 339–344 (2000). CASPubMed Google Scholar
Fox, N. C. et al. Presymptomatic hippocampal atrophy in Alzheimers disease — a longitudinal MRI study. Brain119, 2001–2007 (1996). PubMed Google Scholar
Thompson, P. M. et al. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci.23, 994–1005 (2003). CASPubMed Google Scholar
Silverman, D. H. S. et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA286, 2120–2127 (2001). CASPubMed Google Scholar
Zhuang, Z. P. et al. Structure–activity relationship of imidazo. J. Med. Chem.46, 237–243 (2003). CASPubMed Google Scholar
Cagnin, A., Gerhard, A. & Banati, R. B. In vivo imaging of neuroinflammation. Eur. Neuropsychopharmacol.12, 581–586 (2002). Outline of possible PET studies using [11C] PK11195 for the identification of activated microglia as biomarker for active CNS disease. CASPubMed Google Scholar
Frank, R. et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the Biological Markers Working Group; NIA Initiative on Neuroimaging in Alzheimers Disease. Neurobiol. Aging24 (in the press).
Sunderland, T. et al. Decreased β-amyloid 1-42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA289, 2094–2103 (2003). Preliminary studies and meta-analysis supporting the view that decreases in cerebrospinal fluid Aβ1–42 and increased cerebrospinal fluid Tau could be biomarkers for predictive diagnostic or treatment evaluation of disease modifying therapies in Alzheimer's disease. PubMed Google Scholar
Gurwitz, D. Targeting Alzheimer's disease: Is there a light at the end of the tunnel? Drug Dev. Res.56, 45–48 (2002). CAS Google Scholar
Selkoe, D. J. Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev.81, 741–766 (2001). CASPubMed Google Scholar
Morris, J. C. & Price, J. L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci.17, 101–118 (2001). CASPubMed Google Scholar
Petersen, R. C. et al. Current concepts in mild cognitive impairment. Arch. Neurol.58, 1985–1992 (2001). CASPubMed Google Scholar
Trojanowski, J. Q. Alzheimer's disease centers and the dementias of aging program of the national institute on aging: A brief overview. J. Alzheimer's Dis.3, 249–251 (2001). Google Scholar
Duffy, M. J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem.47, 624–630 (2001). CASPubMed Google Scholar
Grizzle, W. E., Manne, U., Jhala, N. C. & Weiss, H. L. Molecular characterization of colorectal neoplasia in translational research. Arch. Pathol. Lab. Med.125, 91–98 (2001). CASPubMed Google Scholar
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst.92, 205–216 (2000). CASPubMed Google Scholar
Hopper, K. D., Singapuri, K. & Finkel, A. Body CT and oncologic imaging. Radiology215, 27–40 (2000). CASPubMed Google Scholar
Yankelevitz, D. F., Reeves, A. P., Kostis, W. J., Zhao, B. & Henscke, C. I. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology217, 251–256 (2000). CAS Google Scholar
Henschke C. I. et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet354, 99–105 (1999). CASPubMed Google Scholar
Gupta, N. C., Graeber, G. M., Rogers, J. S. & Bishop, H. A. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann. Surgery.229, 286–291 (1999). CAS Google Scholar
Van den Abbeele, A. D. & Badawi, R. D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer38, S60–65 (2002). PubMed Google Scholar
Eubank, W. B. et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics22, 5–17 (2002). PubMed Google Scholar
Mortimer, J. E. et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J. Clin. Oncol.19, 2797–2803 (2001). CASPubMed Google Scholar
Shields, A. et al. Imaging proliferation in vivo with [F-18] and positron emission tomography. Nature Med.4, 1334–1336 (1998). CASPubMed Google Scholar
Eriksson, B. et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann. NY Acad. Sci.970 159–169 (2002). CASPubMed Google Scholar
Mankoff, D. A., Dehdashti, F. & Shields, A. F. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia2, 71–88 (2000). CASPubMedPubMed Central Google Scholar
Chin, B. B. et al. Quantitative evaluation of 2-deoxy-2-[18F] fluoro-D-glucose uptake in hepatic metastases with combined PET-CT: Iterative reconstruction with CT attenuation correction versus filtered back projection with 68Germanium attenuation correction. Mol. Imag. Biol.4, 399–409 (2002). Google Scholar
Beyer, T., Townsend, D. W. & Blodgett, T. M. Dual-modality PET/CT tomography for clinical oncology. Q. J. Nucl. Med.46, 24–34 (2002). CASPubMed Google Scholar
Antoch, G. et al. Whole-body positron emission tomography-CT: Optimized CT using oral and IV contrast materials. Am. J. Roentgenol.179, 1555–1560 (2002). Google Scholar
Masood, S. Standardization of immunobioassays as surrogate endpoints. J. Cell. Biochem.19, S28–S35 (1994). Google Scholar
Grouse, L. H., Munson, P. J. & Nelson, P. S. Sequence databases and microarrays as tools for identifying prostate cancer biomarkers. Urology57, 154–159 (2001). CASPubMed Google Scholar
Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet.24, 236–244 (2000). CASPubMed Google Scholar
Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med.8, 68–74 (2002). CASPubMed Google Scholar
Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98, 10869–10874 (2001). CASPubMed Google Scholar
Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature406, 536–540 (2000). CASPubMed Google Scholar
Van't Veer, L. J. & De Jong, D. The microarray way to tailored cancer treatment. Nature Med.8, 13–14 (2002). CAS Google Scholar
Di Leo, A. et al. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int. J. Clin. Oncol.7, 245–53 (2002). CASPubMed Google Scholar
Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med.346, 1937–1947 (2002). PubMed Google Scholar
Simon, R., Radmacher, M. D., Dobbin, K. & McShane, L. M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. Cancer Spectrum95, 14–18 (2003). CASPubMed Google Scholar
Quackenbush, J. Computational analysis of microarray data. Nature Rev. Genet.2, 418–427 (2001). CASPubMed Google Scholar
Raap, D. a. V. d. K., LD. Mini-review: selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci.65 (1999).
Grillon, C., Codova, J., Levine, L. R. & Morgan, C. A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY 354740) in the fear potentiated startle paradigm in humans. Psychopharmacology 2003 April 23 (DOI: 10.1007/s00213-003-1444-8).
Riba, J. et al. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: A dose response study. Psychopharmacology157, 358–367 (2001). CASPubMed Google Scholar
Guimares, F. S. et al. A simple simulated public speaking test for evaluating anxiolytic drugs. Braz. J. Med. Biol. Res.22, 1083–1089 (1989). Google Scholar
Abelson, J. L., Weg, J. G., Nesse, R. M. & Curtis, G. C. Neuroendocrine responses to laboratory panic: cognitive intervention in the doxapram model. Psychoneuroendocrinology21, 375–390 (1996). CASPubMed Google Scholar
Liebowitz, M. R. et al. Effects of intravenous diazepam pretreatment on lactate-induced panic. Psychiatry Res.58, 127–138 (1995). CASPubMed Google Scholar
Valenca, A. M. N. A., Nascimento, I., Zin, W. A. & Versiani, M. Carbon dioxide test as an additional clinical measure of treatment response in panic disorder. Arq. Neuropsiquiatr.60, 358–361 (2002). PubMed Google Scholar
de Visser, S. J. et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br. J. Clin. Pharmacol.55, 39–50 (2003). CASPubMedPubMed Central Google Scholar
Lesko, L. J., Rowland, M., Peck, C. C. & Blaschke, T. F. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur. J. Pharm. Sci.10, iv–xiv (2000). CASPubMed Google Scholar
Cherry, S. R. & Gambhir, S. S. Use of positron emission tomography in animal research. ILAR J.42, 219–232 (2001). CASPubMed Google Scholar
Hargreaves, R. Imaging substance P NK1 Receptors in the living human brain using positron emission tomography. J. Clin. Psychiatry63, 18–24 (2003). Google Scholar
Chawla, S. P. et al. Establishing the dose of the oral NK-1 antagonist MK-869 for chemotherapy-induced nausea and vomiting. Am. Soc. Clin. Oncol. A1527 (2001).
Bradley, M. M., Cuthbert, B. N. & Lang, P. J. Picture media and emotion — effects of a sustained affective context. Psychophysiology33, 662–670 (1996). CASPubMed Google Scholar
Cuthbert, B. N., Bradley, M. M. & Lang, P. J. Probing picture perception — activation and emotion. Psychophysiology33, 103–111 (1996). CASPubMed Google Scholar
Sheline, Y. I. et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. Biol. Psychiatry50, 651–658 (2001). CASPubMed Google Scholar
Gross, J. J. & Levenson, R. W. Emotion elicitation using films. Cognition Emotion9, 87–108 (1995). Hollywood knows that films are better than still photographs for eliciting emotion and so their use in neuropsychiatry research will no doubt increase. Google Scholar
Rottenberg, J., Gross, J. J., Wilhelm, F. H. & Gotlib, I. H. Crying threshold and intensity in major depressive disorder. J. Abnorm. Psychol.111, 302–312 (2002). PubMed Google Scholar
Yamasaki, H., LaBar, K. S. & McCarthy, G. Dissociable prefrontal brain systems for attention and emotion. Proc. Natl Acad. Sci. USA99, 11447–11451 (2002). CASPubMed Google Scholar
Ploghaus, A. et al. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J. Neurosci.21, 9896–9903 (2001). CASPubMed Google Scholar
Wise, R. G. et al. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage16, 999–1014 (2002). PubMed Google Scholar
Borsook, D. & Bercerra, L. Utilizing brain imaging for analgesic drug development. Curr. Opin. Investig. Drugs3, 1342–1347 (2002). Use of MRI as a means to dissociate the sensory, affective, and cognitive components of pain, providing a potential paradigm to screen for CNS activity of novel drugs. CASPubMed Google Scholar
Peterfy, C. G. Imaging of the disease process. Curr. Opin. Rheumatol.14, 590–596 (2002). Comprehensive overview of magnetic resonance imaging approaches to osteoarthritis. PubMed Google Scholar
Rudin, M. & Weissleder, R. Molecular imaging in drug discovery and development. Nature Rev. Drug Discov.2, 123–131 (2003). A thorough review of emerging imaging technology and its application to clinical studies of new drugs. CAS Google Scholar
Santos-Rosa, H. et al. Active genes are tri-methylated at K4 of histone H3. Nature419, 407–411 (2002). CASPubMed Google Scholar
Weiss, S. T., Silverman, E. K. & Palmer, L. J. Case-control association studies in pharmacogenetics. Pharmacogenomics J.1, 157–8 (2001). CASPubMed Google Scholar
Kiberstis, P. & Roberts, L. It's not just the genes. Science296, 685 (2002). CAS Google Scholar
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & (CBER). Guidance for Industry In Vivo Drug Metabolism/Drug Interaction Studies — Study Design, Data Analysis, and Recommendations for Dosing and Labeling (1999).
Venkatakrishnan, K., Von Moltke, L. L. & Greenblatt, D. J. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther.297, 326–337 (2001). CASPubMed Google Scholar
Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E. & Hines, R. N. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res.51, 236–243 (2002). CASPubMed Google Scholar
Sonnier, M. & Cresteil, T. Delayed ontogenesis of cyp1a2 in the human liver. Eur. J. Biochem.251, 893–898 (1998). CASPubMed Google Scholar
Leeder, J. S. Pharmacogenetics and pharmacogenomics. Pediatr. Clin. North Am.48, 765–781 (2001). CASPubMed Google Scholar
Hoggard, P. G. & Back, D. J. Intracellular pharmacology of nucleoside analogues and protease inhibitors: Role of transporter molecules. Curr. Opin. Infect. Dis.15, 3–8 (2002). CASPubMed Google Scholar
SenGupta Dhruba, J. et al. A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Biochemistry41, 1512–1519 (2002). CASPubMed Google Scholar
Tanaka, C., Kawai, R. & Rowland, M. Physiologically based pharmacokinetics of cyclosporine a: reevaluation of dose-nonlinear kinetics in rats. J. Pharmacokinet. Biopharm.27, 597–623 (1999). CASPubMed Google Scholar
Slapak, C. A., Dahlheimer, J. & Piwnica-Worms, D. Reversal of multidrug resistance with LY335979: Functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo. J. Clin. Pharmacol.41, 29S–38S (2001). CASPubMed Google Scholar
Conrad, S. et al. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics12, 321–330 (2002). CASPubMed Google Scholar
Dresser, G. K., Schwarz, U. I., Wilkinson, G. R. & Kim, R. B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther.73, 41–50 (2003). CASPubMed Google Scholar
Unadkat, J. D., Link, J., Muzi, M., Dupuis, A. & Mankoff, D. In vivo P-glycoprotein (P-gp) transport activity in the pregnant M. nemestrina as measured by biodistribution of (11C)–verapamil and positron emission tomography (PET). J. Med. Primatol.31, 308 (2002). Google Scholar
Ballinger, J. R. Tc-99m-tetrofosmin for functional imaging of P-glycoprotein modulation in vivo. J. Clin. Pharmacol. (2001).
Wandel, C., Kim, R., Wood, M. & Wood, A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology96, 913–920 (2002). CASPubMed Google Scholar
Drysdale, C. et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci.97, 10483–10488 (2000). CASPubMed Google Scholar
Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov.1, 683–695 (2002). The authors describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient. CAS Google Scholar
Walton, I. D. et al. A microvolume laser scanning cytometry platform for biological marker discovery. Proc. SPIE3926, 192–201 (2000). CAS Google Scholar
Wang, W. et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Submitted for publication (2003).
Crabb, J. W. et al. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc. Natl Acad. Sci. USA99, 14682–14687 (2002). This paper gives new insights into the composition of Drusen, a putative biomarker of age-related macular degeneration, that could reveal more on the disease etiology and suggest new therapeutic targets. CASPubMed Google Scholar
Brindle, J. T. et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics. Nature Med.8, 1439–1444 (2002). CASPubMed Google Scholar
Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet359, 572–577 (2002). CASPubMed Google Scholar
Renwick, A. G. & Walton, K. The use of surrogate endpoints to assess potential toxicity in humans. Toxicol. Lett.120, 97–110 (2001). CASPubMed Google Scholar
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (2002).
Kantor, A. B. et al. Biomarker discovery by comprehensive phenotyping for autoimmune diseases. Clin. Immunol. (in the press).
den Broeder, A. A. et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis.61, 311–318 (2002). CASPubMedPubMed Central Google Scholar
Neuhold, L. A. et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest.107, 35–44 (2001). CASPubMedPubMed Central Google Scholar
Cunnane, G., FitzGerald, O., Beeton, C., Cawston, T. E. & Bresnihan, B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum.44, 2263–2274 (2001). CASPubMed Google Scholar
Bayliss, M. T., Hutton, S., Hayward, J. & Maciewicz, R. A. Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: The influence of age, topography and zone of tissue. Osteoarth. Cartil.9, 553–560 (2001). CAS Google Scholar
Armstrong, B. & Doll, R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int. J. Cancer15, 617–631 (1975). CASPubMed Google Scholar
Wakeland, E. K., Liu, K., Graham, R. R. & Behrens, T. W. Delineating the genetic basis of systemic lupus erythematosus. Immunity15, 397–408 (2001). CASPubMed Google Scholar
Cummings, D. E. & Schwartz, M. W. Genetics and pathophysiology of human obesity. Annu. Rev. Med.54, 453–457 (2003). CASPubMed Google Scholar
Townsend, D. W. & Beyer, T. A combined PET/CT scanner: the path to true image fusion. Br. J. Radiol.75, S24–S30 (2002). PubMed Google Scholar
Katz, R., Wagner, H. N., Fauntleroy, M., Kuwert, T. & Frank, R. The use of imaging as biomarkers in drug development: Regulatory issues worldwide. J. Clin. Pharmacol.41, 118S–126S (2001). CASPubMed Google Scholar
Schwaiger, M. Functional imaging for assessment of therapy. Br. J. Radiol.75, S67–S73 (2002). PubMed Google Scholar
Ferguson, S. M. Licensing and distribution of research tools: National institutes of health perspective. J. Clin. Pharmacol. 110S–112S (2001).
Esmond, R. W. The patenting of tools for drug discovery and development. J. Clin. Pharmacol. 112S–115S (2001).